Jochen Seufert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/313219/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1834-1844.	27.0	3,898
2	Physiology and role of irisin in glucose homeostasis. Nature Reviews Endocrinology, 2017, 13, 324-337.	9.6	403
3	Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes and Endocrinology,the, 2013, 1, 115-122.	11.4	153
4	Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes, Obesity and Metabolism, 2018, 20, 620-628.	4.4	121
5	Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in <scp>E</scp> urope and the <scp>USA</scp> . Diabetes, Obesity and Metabolism, 2017, 19, 1155-1164.	4.4	100
6	Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid, 2021, 31, 1076-1085.	4.5	96
7	Stem cells in the treatment of diabetes mellitus — Focus on mesenchymal stem cells. Metabolism: Clinical and Experimental, 2019, 90, 1-15.	3.4	88
8	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 880-893.	11.4	86
9	SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2015, 8, 543.	2.4	51
10	Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as addâ€on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2598-2607.	4.4	48
11	Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries. Diabetes Care, 2017, 40, e139-e140.	8.6	44
12	The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. Diabetes/Metabolism Research and Reviews, 2021, 37, e3430.	4.0	44
13	Preventive medicine of von Hippel–Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	3.1	42
14	Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. Cardiovascular Diabetology, 2019, 18, 33.	6.8	42
15	17q12 Deletion Syndrome as a Rare Cause for Diabetes Mellitus Type MODY5. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3601-3610.	3.6	39
16	Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Research and Clinical Practice, 2016, 115, 31-38.	2.8	38
17	Thyroid function, reduced kidney function and incident chronic kidney disease in a community-based population: the Atherosclerosis Risk in Communities study. Nephrology Dialysis Transplantation, 2017, 32, gfw301.	0.7	33
18	2-Year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes. Diabetes Research and Clinical Practice, 2008, 79, 453-460.	2.8	29

JOCHEN SEUFERT

#	Article	IF	CITATIONS
19	Rationale for Timely Insulin Therapy in TypeÂ2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes Therapy, 2020, 11, 1645-1666.	2.5	27
20	Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, doubleâ€blind, phase 2 trial. Diabetes, Obesity and Metabolism, 2021, 23, 2595-2599.	4.4	27
21	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. European Journal of Endocrinology, 2018, 178, 605-611.	3.7	26
22	Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4078-4086.	3.6	25
23	Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?. Molecular Metabolism, 2022, 64, 101549.	6.5	23
24	Event Rates and Risk Factors for the Development of Diabetic Ketoacidosis in Adult Patients With Type 1 Diabetes: Analysis From the DPV Registry Based on 46,966 Patients. Diabetes Care, 2019, 42, e34-e36.	8.6	22
25	Comparative efficacy and safety of the duodenalâ€jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. Diabetes, Obesity and Metabolism, 2018, 20, 1868-1877.	4.4	20
26	Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocrine Disorders, 2015, 15, 54.	2.2	19
27	A fixed-dose combination of pioglitazone and metformin:a promising alternative in metabolic control. Current Medical Research and Opinion, 2006, 22, S39-S48.	1.9	14
28	Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner. Surgery for Obesity and Related Diseases, 2018, 14, 769-779.	1.2	14
29	<scp>Realâ€world</scp> data of 12â€month adjunct sodiumâ€glucose coâ€transporterâ€2 inhibitor treatment i type 1 diabetes from the <scp>German/Austrian DPV</scp> registry: Improved <scp>HbA1c</scp> without diabetic ketoacidosis. Diabetes, Obesity and Metabolism, 2022, 24, 742-746.	n 4.4	14
30	Comparative Dose Accuracy of Durable and Patch Insulin Pumps Under Laboratory Conditions. Diabetes Technology and Therapeutics, 2019, 21, 371-378.	4.4	13
31	NUPR1 preserves insulin secretion of pancreatic β-cells during inflammatory stress by multiple low-dose streptozotocin and high-fat diet. American Journal of Physiology - Endocrinology and Metabolism, 2020, 319, E338-E344.	3.5	13
32	Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis. BMC Nephrology, 2021, 22, 184.	1.8	13
33	Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 2020, 36, 571-581.	1.9	12
34	Mesenchymal stem cell (MSC)-mediated survival of insulin producing pancreatic β-cells during cellular stress involves signalling via Akt and ERK1/2. Molecular and Cellular Endocrinology, 2018, 473, 235-244.	3.2	11
35	Types of diabetes are not limited to age groups: type 1 diabetes in adults and type 2 diabetes in children and adolescents , 2019, 4, 29-49.		11
36	Effectiveness and safety of insulin glargine 300 U/mL in insulinâ€naÃ⁻ve patients with type 2 diabetes after failure of oral therapy in a realâ€world setting. Diabetes, Obesity and Metabolism, 2020, 22, 759-766.	4.4	10

JOCHEN SEUFERT

#	Article	IF	CITATIONS
37	Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome. Obesity Surgery, 2020, 30, 1200-1210.	2.1	10
38	Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Vascular Health and Risk Management, 2013, 9, 711.	2.3	9
39	Minimally invasive treatment of a duodenal perforation associated with the EndoBarrier duodenal–jejunal bypass liner. Endoscopy, 2014, 46, E171-E172.	1.8	9
40	Value of MRI and MRS fat measurements to complement conventional screening methods for childhood obesity. Journal of Magnetic Resonance Imaging, 2015, 42, 1214-1222.	3.4	9
41	Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German <scp>DIVE</scp> and <scp>DPV</scp> registries. Diabetes, Obesity and Metabolism, 2017, 19, 61-69.	4.4	9
42	Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. Diabetes, Obesity and Metabolism, 2019, 21, 439-443.	4.4	9
43	Clinical Impact of the TCF7L2 Gene rs7903146 Type 2 Diabetes Mellitus Risk Polymorphism in Women with Gestational Diabetes Mellitus: Impaired Glycemic Control and Increased Need of Insulin Therapy. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 663-666.	1.2	9
44	Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT. Clinical Nuclear Medicine, 2020, 45, 519-524.	1.3	9
45	Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL). Obesity Surgery, 2018, 28, 2187-2196.	2.1	8
46	Regional differences in type 2 diabetes treatment and outcomes in Germany—An analysis of the German DPV and DIVE registries. Diabetes/Metabolism Research and Reviews, 2018, 34, e3049.	4.0	8
47	Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen. BMJ Open Diabetes Research and Care, 2019, 7, e000679.	2.8	8
48	Titration of insulin glargine 100ÂU/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study. Acta Diabetologica, 2020, 57, 89-99.	2.5	7
49	Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882095829.	3.2	7
50	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. Diabetes, Obesity and Metabolism, 2020, 22, 346-354.	4.4	6
51	Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. BMC Gastroenterology, 2018, 18, 118.	2.0	5
52	Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries. Advances in Therapy, 2019, 36, 1628-1641.	2.9	5
53	Patientâ€reported outcomes in adults with type 1 diabetes in global realâ€world clinical practice: The <scp>SAGE</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1892-1901.	4.4	5
54	Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Followâ€up (<scp>DPV)</scp> database. Diabetes, Obesity and Metabolism, 2022, 24, 727-732.	4.4	5

JOCHEN SEUFERT

#	Article	IF	CITATIONS
55	Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries. Acta Diabetologica, 2020, 57, 229-236.	2.5	4
56	Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. Vascular Health and Risk Management, 2015, 11, 569.	2.3	3
57	Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment – A prospective observational study in 2202 patients. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 51-57.	3.6	3
58	Ischemic Duodenal Ulceration after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report. Case Reports in Gastroenterology, 2018, 12, 352-359.	0.6	3
59	Comparative Characteristics of Patients with Type 2 Diabetes Mellitus Treated by Bariatric Surgery Versus Medical Treatment: a Multicentre Analysis of 277,862 Patients from the German/Austrian DPV Database. Obesity Surgery, 2018, 28, 3366-3373.	2.1	3
60	Predictors of treatment response in typeâ€2 diabetes patients initiating basalâ€supported oral therapy with insulin glargine 100 U/mL: A subâ€analysis of the Titration and OPtimisation (TOP) registry. Diabetes, Obesity and Metabolism, 2019, 21, 2169-2173.	4.4	3
61	Switching the basal insulin to insulin glargine 300 U/ <scp>ml</scp> in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety. Diabetes, Obseity and Metabolism, 2022, 24, 72-81.	4.4	3
62	The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany. BMJ Open Diabetes Research and Care, 2020, 8, e001486.	2.8	2
63	Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial. Trials, 2021, 22, 285.	1.6	2
64	Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-NaÃ ⁻ ve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study. Diabetes Therapy, 2021, 12, 733-747.	2.5	1
65	Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study. Diabetes Therapy, 2021, 12, 749-764.	2.5	1
66	Disease heterogeneity of adult diabetes based on routine clinical variables at diagnosis: Results from the German/Austrian Diabetes Followâ€up Registry. Diabetes, Obesity and Metabolism, 2022, 24, 2253-2262.	4.4	1
67	The backbone of oral glucoseâ€lowering therapy: time for a paradigm shift?. Fundamental and Clinical Pharmacology, 2009, 23, 651-667	1.9	0
68	Durch Förderung des diabetologischen Nachwuchses in der DDG exzellente Forschung und Patientenversorgung zukunftssicher aufstellen – Hellmut-Otto-Medaille 2021 - KurzA¼bersicht der PreistrÄ́ger Annette Schļrmann und Jochen Seufert. Diabetologie Und Stoffwechsel, 2021, 16, 467-468.	0.0	0